Amarin | AMRN - Assets

Stock Price
14.56
Daily Change
-0.22 -1.49%
Monthly
-1.09%
Yearly
37.62%
Q2 Forecast
14.12

Amarin reported $645.76M in Assets for its fiscal quarter ending in March of 2026.





Assets Change Date
AbbVie USD 136.46B 2.5B Mar/2026
Alnylam Pharmaceuticals USD 5.13B 163.22M Mar/2026
Amarin USD 645.76M 25.01M Mar/2026
AstraZeneca USD 114.02B 59M Mar/2026
BioCryst Pharmaceuticals USD 465.05M 49.11M Mar/2026
DBV Technologies USD 233.72M 123.22M Dec/2025
Esperion Therapeutics USD 462.53M 3.36M Mar/2026
GlaxoSmithKline GBP 62.87B 1.75B Mar/2026
Halozyme Therapeutics USD 2.67B 147.4M Mar/2026
Heron Therapeutics USD 246.22M 9.66M Mar/2026
Ionis Pharmaceuticals USD 3.45B 74M Mar/2026
Nektar Therapeutics USD 280.41M 20.94M Dec/2025
Neurocrine Biosciences USD 4.91B 274.7M Mar/2026
Novartis USD 118.53B 7.58B Mar/2026